Journal Information
Vol. 42. Issue S1.
Pages 33-34 (October 2020)
Share
Share
Download PDF
More article options
Vol. 42. Issue S1.
Pages 33-34 (October 2020)
OP 30
Open Access
Gastroenteropancreatic neuroendocrine carcinoma: single center experience
Visits
1218
A. Sakin1, O. Can2,*
1 Internal Medicine Clinic, Van Training and Research Hospital, Van, Turkey
2 Medical Oncology Clinic, Okmeydani Training and Research Hospital, Istanbul, Turkey
This item has received

Under a Creative Commons license
Article information
Full Text

Objective: In general, all high grade, poorly differentiated gastrointestinal neuroendocrine carcinomas (GIS-NEC) exhibit aggressive behavior characterized by widespread metastases in the early stages. It relapses very quickly, even in the early stages. The prognosis is extremely poor. These tumors show similarities with small cell carcinoma of the lung in terms of morphology, biological behavior and chemosensitivity. In this study, we aimed to investigate survival according to primary tumor localization and the stage besides clinical and demographic data of GIS-NECs.

Methodology: Twenty-seven patients with the diagnosis of GIS-NEC were included in the study. Patients under the age of 18, patients with another malignancy other than GIS-NEC and patients having GIS NEC but whose data were missed, were not included in the study.

Results: In this study, 15 male (55.6%) and 12 female (44.4%) patients were included. Median age was 66 years old. The primary localizations were as follows, in 15 (55.6%) patients; gastric, in 4 (14.8%) patients; esophagus, in 4 (14.8%) patients; colorectal, in 2 (7.4%) patients; pancreas and in 2 (7.4%) patients; small intestine. At the time of diagnosis, in 21 (77.8%) patients Stage 4 disease, in 5 (18.5%) patients stage 2 and 3 disease and in 1 (3.7%) patients stage 1 disease was present. During the follow-up, 16 (59.3%) patients were ended up with exitus. Feature characteristics of the patients were summarized in (Table 1). While median survival was not achieved in stage 2 and 3 patients, it was 8 months in stage 4 patients. (Figure 1). Based on the primary tumor localization, mOS was 7 months in the gastric, 5 months in the pancreas, 7 months in the small intestine, 6 months in the esophagus. In colorectal localization mOS could not be reached (Table 2).

Conclusion: In our study, gastric localization was the most common in GIS-NECs. The shortest survival was observed in the pancreatic localization.

Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools